Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StaphVAX 3rd and 4th Dose in ESRD (SHIELD-2)
NCT00130260Phase 3Terminated
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Aug 2005
- Primary completion
- Dec 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of s. aureus type 5 & 8 capsular polysaccharide vaccine in staphylococcal infection (4 arms), sponsored by Nabi Biopharmaceuticals. Primary endpoint: Serotype-specific antibody concentrations. Started Aug 2005; status: terminated.
02
Drugs
s. aureus type 5 & 8 capsular polysaccharide vaccine
03
Conditions
staphylococcal infection
Beyond the preview
Go deeper on NCT00130260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130260.